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Abstract (298/300 words) 
There is an increasing need in biology and clinical medicine to robustly and reliably 
measure tens-to-hundreds of peptides and proteins in clinical and biological samples 
with high sensitivity, specificity, reproducibility and repeatability. Previously, we 
demonstrated that LC-MRM-MS with isotope dilution has suitable performance for 
quantitative measurements of small numbers of relatively abundant proteins in human 
plasma, and that the resulting assays can be transferred across laboratories while 
maintaining high reproducibility and quantitative precision. Here we significantly extend 
that earlier work, demonstrating that 11 laboratories using 14 LC-MS systems can 
develop, determine analytical figures of merit, and apply highly multiplexed MRM-MS 
assays targeting 125 peptides derived from 27 cancer-relevant proteins and 7 control 
proteins to precisely and reproducibly measure the analytes in human plasma. To 
ensure consistent generation of high quality data we incorporated a system suitability 
protocol (SSP) into our experimental design. The SSP enabled real-time monitoring of 
LC-MRM-MS performance during assay development and implementation, facilitating 
early detection and correction of chromatographic and instrumental problems. Low to 
sub-nanogram/mL sensitivity for proteins in plasma was achieved by one-step 
immunoaffinity depletion of 14 abundant plasma proteins prior to analysis. Median intra- 
and inter-laboratory reproducibility was <20%, sufficient for most biological studies and 
candidate protein biomarker verification. Digestion recovery of peptides was assessed 
and quantitative accuracy improved using heavy isotope labeled versions of the proteins 
as internal standards.  Using the highly multiplexed assay, participating laboratories 
were able to precisely and reproducibly determine the levels of a series of analytes in 
blinded samples used to simulate an inter-laboratory clinical study of patient samples. 
Our study further establishes that LC-MRM-MS using stable isotope dilution, with 
 5 
appropriate attention to analytical validation and appropriate quality c`ontrol measures, 
enables sensitive, specific, reproducible and quantitative measurements of proteins and 
peptides in complex biological matrices such as plasma. 
 
Introduction  
Biology and clinical medicine are increasingly in need of methods to robustly and reliably 
measure many tens to hundreds of peptides and proteins in a given sample with high 
sensitivity, specificity and reproducibility. Targeted mass spectrometry (MS) methods 
offer biologists and clinical researchers an ever-increasing suite of experimental 
approaches and data analysis tools to accomplish this task without the need for 
immunoassays (1-4). With rapid advances in sample processing, instrument hardware 
and data acquisition software over the past 10 years, liquid chromatography multiple 
reaction monitoring mass spectrometry (LC-MRM-MS) using stable isotope labeled 
peptide standards has matured into a robust approach for peptide-based protein 
quantification. This approach is available to any laboratory with access to a triple 
quadrupole mass spectrometer interfaced with a high performance LC system. Ever 
increasing refinement of targeted LC-MS methods has positioned this technique as an 
attractive workflow for verification of candidate protein biomarkers in the clinical arena, 
as well as biology (5-26). Achievable limits of quantification (LOQs) can be in the ng/mL 
to low µg/mL range with coefficients of variation (CVs) <20% which are suitable for 
verification studies in clinical or biological contexts (5, 9, 14, 18, 26, 27). Furthermore, 
coupling peptide immunoaffinity enrichment with LC-MRM-MS allows for limits of 
detection (LODs) that approach those of ELISA assays (low pg/mL) (28-30) and intra- 
and interlaboratory CVs of <15% (31).  
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Despite numerous reports describing the application of LC-MRM-MS for 
quantification of target peptides, questions remain about the sensitivity, specificity, 
reproducibility, quantitative precision and accuracy of the measurements as well as the 
transferability of the methods and assays across laboratories. These questions are 
driven, in part, by the lack of methodological detail or rigorous analytical validation of 
targeted MS measurements in many published studies, preventing readers from 
understanding how well the assays work or to be able to implement the described 
assays in their own laboratories (10). Since 2005 the Clinical Proteomics Technology 
Assessment for Cancer (CPTAC) network of the National Cancer Institute has had, as 
one area of focus, the evaluation, refinement and application of LC-MRM-MS 
methodology for peptide-based verification of proteins and their modifications in biofluids 
and tissue. Our efforts have focused on making these assays more precise, accurate, 
reproducible and transferable between different laboratories, expertise levels, and LC-
MS instrument platforms with the goal of widespread adoption initially by the proteomics 
community, but ultimately also by the clinical laboratory and biology communities. 
Previously, we demonstrated the reproducibility and transferability of peptide-based 
MRM assays across eight laboratories (5) by measuring levels of 10 signature peptides 
representing seven proteins that were spiked across a defined concentration range (1-
500 fmol/µL) into neat human plasma. The study was performed in three phases 
whereby each phase introduced additional sources of variability in sample preparation 
and instrumental analyses. In the final phase, which included all sources of variability 
including proteolytic digestion, the median interlaboratory CV of the eight peptides 
consistently detected was ≤20% across the concentration range tested. This study 
demonstrated the implementation of a targeted, quantitative and multiplexed LC-MRM-
MS assay across multiple laboratories to reproducibly measure a small number of 
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proteins present at moderate to high abundance (≥2-6 µg/mL in plasma) yielding CVs in 
an acceptable range for biomarker verification studies (10, 27, 32).  
Here we significantly expand upon our previous work, detailing critical steps in the 
assay development phase essential for successful development of highly multiplexed 
MRM assays, including the use of a system suitability protocol (SSP) (33) to monitor LC-
MRM-MS performance during assay development to detect and correct problems early. 
We also highlight key advances in hardware and software that we have incorporated into 
the current design that became available since our initial study. The present study 
utilized 8 different LC-MS instrument configurations in 11 separate laboratories on a total 
of 14 individual systems to target and quantitatively measure >100 peptides from a total 
of 34 proteins, including 27 that are cancer relevant (Table 1). Similar considerations on 
a smaller scale have been recently discussed using protein and peptide standards as 
part of quality control for large quantitative studies (34).  In our study, sensitivity for 
proteins in plasma was increased into the low-to-sub nanogram/mL level by one-step 
immunoaffinity depletion as well as gradient optimization to maximize the 
chromatographic resolution in the sample matrix. Use of heavy-labeled protein internal 
standards added to samples prior to processing greatly improved the accuracy of 
protein-level quantification. Intra- and inter-laboratory reproducibility sufficient for most 
biological studies as well as for candidate protein biomarker verification was achieved. 
Overall, this study demonstrates that highly multiplexed MRM-MS based assays can, 
with appropriate attention to experimental design, analytical validation, and suitable 
quality control measures, be implemented by multiple laboratories to provide sensitive, 
specific, reproducible and quantitative measurements of proteins and peptides of clinical 
and biological interest in complex biological matrices, specifically plasma. 
METHODS 
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Materials   
A tryptic digest of 6 bovine proteins in equamolar mix (P/N PTD/00001/63) was 
purchased from Bruker-Michrom, Inc. (Auburn, CA).  Picofrit columns (75 µm ID, 10 µm 
tip ID) pre-packed with ReproSil-Pur C18-AQ resin (3 µm particle size, Dr. Maisch) were 
purchased from New Objective (Woburn, MA).  Synthetic unlabeled (light) peptides and 
the corresponding stable-isotope labeled (heavy) versions were purchased from Thermo 
Fisher Scientific (San Jose, CA). Twenty-seven proteins were expressed in E. coli in 
both unlabeled (light) and uniformly 15N-labeled forms and purified for use in this study at 
Argonne National Laboratories (Table 1 and Supplemental Table 1).  Pooled and 
filtered (0.2 µm) human K2EDTA plasma was obtained from the National Institute of 
Standards and Technology (NIST).  Plasma delipidation and depletion of the 14 most 
abundant proteins using the Multiple Affinity Removal System (MARS-14) depletion 
column (Agilent, Santa Clara) was performed at Caprion Proteomics, Menlo Park, CA 
(formerly PPD Biomarker Discovery Sciences).  Mass spectrometry grade Trypsin Gold 
was obtained from Promega (Madison, WI).  Iodoacetamide, dithiothreitol and urea were 
purchased from Sigma Chemical Company. 
 
Synthetic peptides and proteins.  Peptides were selected from proteins detected in 
data-dependent experiments in breast cancer samples conducted at the Broad Institute 
(data not shown) and supplemented with publicly available data in GPM and the in silico 
prediction program, ESP Predictor (35).  Between 1 and 5 peptides per protein were 
selected for synthesis, based on the common rules for peptide stability, length, and 
unique sequence. One hundred and twenty-five synthetic peptides were purchased in 
their unlabeled and labeled form, the latter containing C-terminal arginine and lysine 
residues as 13C615N4 (R10) and 13C615N2 (K8) analogs, respectively (Table 1).  Of the 125 
 9 
synthetic peptides used in this study, 115 peptides represented new, potentially cancer 
relevant peptide targets (derived from 27 proteins), while 10 peptides (derived from 7 
proteins) were previously assayed in Addona et al. (5).  Peptide and isotopic purity of the 
synthetic peptides was estimated to be >98% as determined by LC-UV and MALDI-MS 
by Thermo Fisher Scientific (San Jose, CA). The concentrations of synthetic peptides 
and target proteins were determined by amino acid analysis.  1:1 mixtures of the heavy 
and light versions of each of the proteins were evaluated in two of the study centers by 
LC-MS/MS following reduction, alkylation and digestion using the same digestion 
protocol used for the plasma samples.  The observed ratios of released peptides were 
close to the expected 1:1 ratios.   Of course, all peptide and protein LODs, LOQs and 
determined amounts of peptides or proteins present are subject to potential inaccuracies 
of amino acid analysis.   Isotopic purity of heavy U-15N-labeled proteins was assessed 
after tryptic digestion at the Buck Institute for Age Research by ESI-MS/MS on a hybrid 
quadrupole time-of-flight QSTAR Elite mass spectrometer (AB SCIEX, Concord, 
Canada). For the resulting tryptic U-15N-labeled peptides, comparisons between the 
observed isotope distributions obtained in the acquired spectra and simulated 
distributions suggested that the isotopic peptide purity was typically >98%.  This process 
was automated using the Isotope Pattern Calculator (IPC) available at PNNL 
(http://omics.pnl.gov/software/IPC.php), that was customized further in-house.   
 
Study Phases: Samples, Sample Preparation, and Experimental Setup   
Study Phase I: This phase (see Figure 1) consisted of MRM assay development 
including selection, testing and optimization of peptide transitions, nano-chromatography 
conditions and LC-MRM operating conditions. Details are found in sections immediately 
below. Assay development was carried out at six of the participating sites using 
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instrument platforms from four vendors (AB SCIEX, ThermoFisher Scientific, Waters and 
Agilent) prior to distribution of peptide reagents and plasma samples for use in Phases II 
and III. A range of heavy spike concentrations were evaluated by these groups using a 
16 point response curve.  From the results obtained, the 9 best concentrations for 
Phases II and III were selected. Conditions for plasma digestion were chosen based on 
digestion studies of 34 protein standards used in the study. Proteins were spiked into 
depleted plasma and digested under various conditions including denaturation with 
deoxycholate (DOC), trifluroethanol (TFE), and urea, as well as assessing the 
subsequent use of two enzymes for digestion (Lys-C/trypsin). The resulting data were 
evaluated for missed cleavage products and maximized peptide recovery. Digestion with 
Lys-C in 2M urea (2 hours) followed by dilution of urea to <1 M and addition of trypsin 
(16 hours) was the most reproducible of the methods evaluated, yielding the lowest 
median % CV for all peptides quantified by SID-MRM-MS. More complete results are 
described elsewhere (36). Reduction and alkylation conditions were as previously 
reported (5).  All sample kits were centrally prepared at Vanderbilt University and 
subsequently distributed to each participating site.  Reagents and samples are described 
in Supplemental Document 1. 
MRM Assay Method Development: MRM-MS transition lists were developed and applied 
to all fourteen participating triple quadrupole mass spectrometers representing four 
different vendors (AB SCIEX, ThermoFisher Scientific, Waters and Agilent).  Skyline (37) 
MRM transition selection for each peptide was performed independently for each 
instrument configuration.  For AB SCIEX and Waters instruments, spectral libraries were 
built in Skyline from data dependent acquisitions (on a 4000 QTRAP, a QSTAR Elite, 
and a QTOF Premier instrument) and peptide search engine results using the BiblioSpec 
library builder (38).  Then, MRM transitions were selected based on the most abundant 
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fragment ions from these discovery platform data.  Alternatively, for ThermoFisher and 
Agilent platforms, the SRM Refinement approach (39) was employed on the triple 
quadrupole MS to determine optimal MRM transitions for each peptide.  For each vendor 
platform the best 5 transitions per peptide based on extracted ion current chromatogram 
peak intensity were selected.  Evaluation of interferences from the plasma and from the 
exogenous peptide spikes was conducted by preparing 3 L:H peptide mixtures in 0.5 
µg/µL plasma: 10:1, 1:1 and 1:10, where the concentrations of the light heavy peptides 
was 1 fmol/µL or 10 fmol/µL to generate the L:H ratios.  Each transition was evaluated to 
ensure the L:H peak area ratio for that sample matched the theoretical ratio in the 
prepared sample and if the ratio deviated by more than 10%, the transition was removed 
from the list.  The final MRM assay culminated in the 3 most abundant and interference-
free transitions per peptide (transitions were selected for the unlabeled, 13C/15N-
isotopically labeled, and U-15N-isotopically labeled version of each peptide).  Collision 
energy values used were based upon linear regression equations provided in Skyline for 
each vendor platform (40).  The final list of MRM transitions for each platform is listed in 
Supplemental Table 2.  Finally, four different Skyline “Instrument Method templates” 
documents (transition lists only) were generated, including all specific MRM transition 
information and were distributed to instrument operators. 
Optimization of reversed phase nanoflow high performance liquid chromatography 
(nanoHPLC):  Peptide mixtures were separated by on-line reversed phase nanoHPLC 
systems equipped with autosamplers: specifically, two NanoLC-1D Plus systems, seven 
NanoLC-2D systems and two NanoLC_Ultra systems (i.e., one NanoLC_Ultra 1D Plus 
and one NanoLC_Ultra 2D Plus) from Eksigent Technologies (Dublin, CA), one Ultimate 
3000 system from Dionex (Sunnyvale, CA), one nanoAquity system (Waters, Milford, 
MA), and two 1100 series systems (Agilent).  Peptide separations were performed on 
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PicoFrit® (New Objective, Woburn, MA) pre-packed columns (75 µm ID x 120 mm, 10 
µm ID tip) packed with ReproSil-Pur C18-AQ (3 µm particle size and 120 Å pore size) 
using a flow rate of 300 nL/min.  Mobile phase compositions were 0.1% (v/v) formic acid 
in water (Solvent A) and 90% (v/v) acetonitrile with 0.1% (v/v) formic acid (Solvent B).  
One microliter injections of the peptide digestion mixtures were separated using a binary 
gradient of 3-7% B in 3 min, 7-25% B in 27 min, 25-40% B in 7 min, 40-90% B in 3 min, 
and at 90% B for 4 min.  All instrument configurations acquired data using a direct 
injection configuration set-up, with the exception of the Agilent ChipCube-LC instruments 
that used an HPLC Chip containing both precolumn (160 nL) and analytical column (75 
µm ID x 150 mm, Zorbax 5 µm or Polaris 3 µm beads). Additional details including 
plumbing configurations and autosampler injection routines are described in the SOP 
(see Supplemental Documents 1 and 2).  Mass Spectrometer Operating Parameters 
are described in detail in Supplemental Document 3.  All MRM transitions are listed in 
Supplemental Table 2 for each instrument platform.  A total of 750 MRM transitions 
were monitored for Phase II and 1095 for Phase III. 
Study Phase II: The samples analyzed in this phase of the study (see Figure 1) were 
prepared centrally at Vanderbilt University. Briefly, samples used to generate a nine-
point response curve were prepared in human MARS-14 depleted K2EDTA plasma.  The 
depleted plasma was denatured, reduced and alkylated, digested with Lys-C and trypsin 
and desalted according to a standard operating procedure (see Supplemental 
Document 1). The resulting digested, depleted plasma was spiked with 125 synthetic 
12C/14N and corresponding 13C/15N-isotopically labeled internal standard (IS) peptides.  
Nine concentration point samples were prepared by serial dilution to generate calibration 
curves spanning a concentration range of 1 amol/µL to 100 fmol/µL (with 1 µL volume 
on-column) of all light peptides spiked into a 0.5 µg/µL background of the depleted 
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plasma digestion with a constant concentration of 10 fmol/µL of all 13C/15N-isotopically 
labeled IS peptides. The individual concentrations of the light peptides were 100.00, 
23.71, 5.62, 1.33, 0.316, 0.075, 0.018, 0.004, 0.001 fmol/µL (loading 1 µL of sample on-
column).  The four calibration curves were generated individually.  In addition, six 
samples, referred to as blinded samples, with light peptide concentrations unknown to 
the instrument operator were provided to each site.  The blinded samples were analyzed 
at the end of each of the four singlicate response curves (see Supplemental Table 3).  
Phase II sample kits were shipped to the 9 participating laboratories (representing 14 LC 
MSMS instrument configurations).  Of the original 11 laboratories involved in Phase II, 2 
were unable to continue with Phase III and were removed from the study.  Additional 
details regarding sample kits, reagents and sample preparation, including details for 
digestion, desalting, sample acquisition order etc. are described in the Phase II SOP 
(see Supplemental Document 1).   
 
Study Phase III: For Phase III (see Figure 1), response curves and blinded samples 
were generated by spiking 27 unlabeled undigested ANL cancer relevant target proteins 
(Table 1) and 6 unlabeled undigested previously characterized proteins (5) into depleted, 
undigested human K2EDTA plasma.  The 9-point response curve for the 27 unlabeled 
cancer relevant proteins spanned a concentration range of 10 amol/µL to 100 fmol/µL 
((loading 1 µL of sample on-column) in a background of depleted human K2EDTA 
plasma (0.5 µg/µL).  The six additional unlabeled proteins, used as a digestion 
reproducibility control, were spiked at a constant concentration such that following 
digestion and dilution, a final on-column amount of 2.5 fmol equivalent was achieved.  In 
addition, 27 U-15N-labeled proteins were spiked into depleted plasma at a constant 
concentration, so that after digestion and dilution yielded 115 U-15N target peptides at 25 
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fmol equivalent on-column.  Samples were prepared such that after protein digestion the 
individual concentrations of the proteolytically generated light peptides were calculated 
to be 100, 24, 5.6, 1.3, 0.82, 0.32, 0.075, 0.018, and 0.010 fmol/µL (1 µL injection 
volume).  In addition, six blinded samples with light protein concentrations unknown to 
the instrument operator at each site were provided and analyzed at the end of each of 
the four singlicate response curves (see Supplemental Table 3).  Phase III sample kits 
with undigested light and heavy proteins spiked into undigested depleted plasma were 
prepared at Vanderbilt University and sent to the 7 participating laboratories 
(representing 11 LC-MRM-MS instrument configurations).  The samples were digested 
and desalted at the individual sites.  MS operators digested 3 independent protein 
calibration sets and blinded samples.  Data for the third protein calibration curve were 
acquired as a technical MS duplicate, so that as in Phase II, there was a total of 4 LC-
MRM-MS acquisition replicates.  All instruments operators spiked the 13C/15N-isotopically 
labeled peptides, post-desalt, to yield a final concentration of 10 fmol/µL.  At 3 
participating sites the 13C/15N-isotopically labeled peptides were spiked in pre- and post-
desalt as independent experiments to assess sample loss during desalting.  Protein 
digestion efficiencies were estimated using U-15N-labeled proteins that had been spiked 
into depleted plasma. Additional details are described in the Phase III SOP (see 
Supplemental Document 2).   
System Suitability Monitoring.  Stock solutions (1 pmol/µL per protein) of the 
commercial predigested “Bovine 6 Protein Mix,” referred to as 6 ProteinMix-QC (33), 
was prepared at Vanderbilt University.  As described in detail in the SOP (see 
Supplemental Documents 1 and 2), prior to analysis, individual CPTAC sites further 
diluted the stock solution to a working solution of 50 fmol/µL 6 ProteinMix-QC and 
monitored prior to and during Phases II and III. 
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LC-MRM-MS Data Acquisition.  Mass spectrometric data were acquired following a 
comprehensive and well-defined run order of all calibration curves and blinded samples 
in quadruplicates per study.  Run orders also included definition of system suitability 
acquisitions to track instrument performance throughout the studies.  Sample setup, 
sample and file naming nomenclature, etc. are described in the accompanying SOP 
(Supplemental Documents 1 and 2).  Scheduled, multiplexed LC-MRM-MS acquisition 
was employed based on the retention times of each peptide monitored.  In preparation 
for the scheduled response curve LC-MRM-MS runs, in which 750 transitions were 
monitored in one run (Phase II), participating sites monitored all synthetic isotopically 
labeled peptides with ~ 375 transitions (125 peptides with 3 transitions each) in 6-7 
unscheduled LC-MRM-MS runs (~60 transitions per run, keeping cycle times ~ 1 sec).  
Retention times for scheduling were determined empirically using these six/seven runs 
and were verified by performing a single scheduled LC-MRM-MS run prior to analyzing 
the response curve samples.  Retention times of all peptides were used to generate a 
single scheduled method with 2 minute retention time windows.  All method building and 
data analysis was performed using Skyline.  
To minimize instrument-to-instrument variability in chromatography, pre-packed PicoFrit 
columns (New Objective, Woburn, MA) were purchased for all sites except for those 
using ChipCube ion sources (Agilent, Santa Clara, CA), Nanoflex cHiPLC dual column 
systems (AB SCIEX, Foster City, CA) chip-based column plumbing, and NanoAcquity 
UHPLC systems (Waters, Milford, MA).  Sites with alternate hardware configurations 
were set up to take advantage of best current available technologies suited to their LC 
systems (see Supplemental Documents 1-3).  
Data Analysis.  Skyline was used as a common data analysis platform across sites that 
fostered sharing of data during acquisition as well as creating final reports from each 
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laboratory.  Raw data files were imported into Skyline which uses the ProteoWizard Data 
Access Library.  The MRM transitions for each peptide were integrated with Skyline to 
generate extracted ion chromatograms which were then manually adjusted, if necessary.  
Skyline peak area calculations based on the final, adjusted peak boundaries were used 
as the primary measure or peptide abundance.  Each site performed their own data 
analyses and Skyline peak boundary adjustments.  Skyline custom reports were used to 
export results from processed MRM data, such as peak areas, peak heights, 
chromatographic parameters, etc.  These data results reports were further processed in 
R statistical programming language (41) and our own cross-site validation tools to 
generate further statistical results and graphics. 
Statistical and Graphical Methods.  Data from MRM-MS experiments were 
preprocessed and integrated in Skyline, and exported as a table in csv format.  A 
uniform processing and Skyline export template was used for all MS instruments, which 
resulted in an output that was instrument independent.  Specific data fields were 
extracted from Skyline and include Sample name, peptide sequence, replicate name, 
retention time, area light, area heavy, full-width-half-maximum (FWHM) peak width, 
fragment ion, precursor charge and product m/z.  These extracted fields were then 
processed using custom developed code written in the R statistical programming 
language (41). QuaSAR, an open source software algorithm was used to generate 
calibration curve regressions and a variety of different plots for each site 
(http://genepattern.broadinstitute.org/gp/pages/index.jsf?lsid=QuaSAR). This link 
prompts the user to login at GenePattern, it also provides free registration at the 
GenePattern website upon choosing ‘click to register’; then under modules browse to 
‘Proteomics’ then to ‘Quasar’ or search for the ‘Quasar’ module directly.  Comprehensive 
plots were generated to analyze not only the overall statistics, e.g. CV, but to provide a 
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more detailed understanding of the LC and MS parameters and measurements from 
replicate to replicate, between sites and across peptides. 
Metrics for Assessing the Performance of the Quantitative MRM Assays.  The 
metrics used for assessing reproducibility of the MRM assays were intra- and inter-Lab 
precision.  Intra-Lab precision was defined as the median CV calculated from replicates 
of each concentration point for a particular peptide for each site study.  Inter-Lab 
precision was defined as the CV calculated at each concentration point for a particular 
peptide across all replicates and sites and for each study. Values for CVs were 
calculated as the ratio of the standard deviation to the mean of the replicate 
measurements at a given concentration.  Both of these assessment metrics were 
determined based on quadruplicate measurements for a single transition used to 
calculate limit of detection (LOD) and limit of quantification (LOQ), see below. 
Determination of LOD and LOQ:  Limit of detection for all monitored peptides from the 9-
point response curve in 0.5 µg/µL depleted plasma were determined as previously 
described (5, 42).  Once the LOD was determined separately for each peptide transition, 
the LOQ was calculated using the customary relation: LOQ = 3 x LOD (43). The LOD 
was based on the variance of the blank sample (sample A, digested depleted plasma 
with the heavy isotope peptides and no analyte spiked in) and the variance of the lowest 
level spike-in sample (sample B, with analyte at 1 amol/µL).  Assuming a type I error rate 
α=0.05 for deciding that the analyte is present when it is not, and a type II error rate 
β=0.05 for not detecting the analyte when it is present, the LOD was derived as:  
LOD = LOB + cβ x SDS 
LOB (limit of blank) was defined as the 95th percentile of the blank A1 samples (44).  
This was estimated as the mean plus t1-β x SDb, where SDb was the standard deviation in 
 18 
the blank samples, and SDS was the standard deviation of the low-level spike in sample 
B.  For a relatively small number of repeated measurements for sample B, cβ was 
approximated as t1-β where t1-β is the (1-β) percentile of the standard t distribution on f 
degrees of freedom, where f is the number of replicates minus 1.  Detailed calculations 
of the various components of the LOD are listed in the QuaSAR LOD/LOQ output tables 
for each site, which are available on the Panorama webserver for the manuscript. 
LOD values are initially calculated for all three transitions monitored for each peptide. 
The transition with the minimum LOD is chosen as the “best” transition. This transition is 
used to report LOD and LOQ for inter- and intra-lab CV calculations. 
Digestion and desalt losses are calculated using Phase III data from the three sites 
where the SIS peptides were spiked in both before and after desalting (pre- and post-
desalt, respectively). Using the slope of the calibration curve as a representation of 
overall recovery for a given peptide, we calculate: 
Digestion loss = Recovery using U15N standard - Recovery using pre-desalt SIS 
Desalt loss = Recovery using pre-desalt SIS – Recovery using post-desalt SIS 
Percentage loss is calculated by normalizing the respective loss to corresponding total 
peptide loss (= digestion loss + desalt loss). The results are averaged over the three 
sites for tabulation (Supplemental Table 8) and visualization (Supplemental Figure 2).  
Public Access to the Data. An ftp server at the National Institute of Standards (NIST) 
was used by the CPTAC teams for initiating uploads and downloads of all data files.  
Currently, all raw data associated with this manuscript is uploaded at Chorus 
(https://chorusproject.org).  The processed, quantitative data associated with this 
manuscript resides at the interactive Panorama webserver:  
‘http://proteome.gs.washington.edu/software/panorama/cptac_study9.html’.  Posted 
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information includes processed data results and downloadable Skyline documents from 
all participating sites. 
 
Results 
Overview of Experimental Design: The experimental design incorporated three discrete 
phases (Figure 1). Phase I consisted of assay development prior to distribution of 
peptide reagents and plasma samples for use by the participating laboratories. Assay 
development included gradient optimization, peptide transition selection, optimization of 
depleted plasma digestion conditions, determination of the heavy peptide spike amount, 
and a 16 point response curve to select the 9 concentrations spanning the linear range 
and below the LOD for Phases II and III. Assay development was conducted at 6 of the 
participating sites and employed instrument platforms from all four vendors. 
In Phase II, samples consisting of depleted plasma spiked with increasing amounts of 
125 peptides (Table 1) from 1 amol to 100 fmol and constant 10 fmol amounts of the 
heavy-labeled versions of each peptide were distributed in quadruplicate to each 
participating site as “ready-to-analyze” kits, together with a detailed analysis protocol 
(Supplemental Document 1).  In addition, six samples with four different analyte 
concentrations (Supplemental Table 3) blinded to the participants were also provided in 
quadruplicate. Some of the 11 participating sites had multiple instruments in the study 
resulting in a total of 14 instruments and 8 distinct LC-MS platforms (see methods and 
Supplemental Document 3).  Each site used a pre-defined and instrument-specific MRM-
MS transition list to establish the retention times of the target peptides in their systems.  
Response curves were generated on each instrument for each of the quadruplicate 
sample sets by analyzing the samples from low to high concentration followed by wash 
and blank runs and then six blinded samples (Supplemental Documents 1 and 2).  In 
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addition, all groups also acquired data for a common quality control sample using a 
system suitability protocol [SSP, (33)] before starting analyses and after every 6-8 
subsequent LC-MRM-MS runs. Phase II primarily evaluated instrument variability as all 
sample preparation, including digestion of depleted plasma, was performed centrally in a 
single laboratory prior to sample distribution.   
In Phase III, variability caused by sample processing and handling, and determination of 
LOD/LOQ were evaluated by having each site reduce, alkylate and trypsin digest 
samples spiked with proteins (vs. spiked peptides) as the source of the analyte peptides 
(Figure 1).  Twenty-seven proteins were expressed in E. coli in both unlabeled (light) 
and uniformly 15N-labeled forms and purified for use in this study at Argonne National 
Laboratories (Supplemental Table 1).  To generate response curves, light proteins 
were spiked into depleted plasma (0.01 – 100 fmol/µL) while the U15N-labeled proteins 
were added as internal standards to evaluate increased accuracy of protein-level 
quantification when using labeled peptides released from labeled proteins during 
enzymatic digestion.  The labeled proteins were also used to assess the extent of 
peptide loss during enzymatic digestion (see below and Supplemental Figure 2 and 
Supplemental Table 8).  Synthetic 13C/15N-labeled versions of all peptide analytes were 
introduced post-desalt of the digest and immediately prior to LC-MRM-MS analysis 
(analogous to Phase II).  The heavy synthetic peptides contain only a single labeled 
amino acid and have different and readily distinguishable masses and transition ions 
compared to the peptides derived from the U15N-proteins in which every nitrogen atom in 
the peptide has been replaced with 15N (Supplemental Table 1).  
While peptide standards are typically spiked in prior to the desalting step to account for 
losses during desalting, (31, 45-49) in this experiment the peptide standards were spiked 
in post-desalt to allow for measurement of percent recovery of targeted peptides from 
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the digested proteins and to assess variability in the reduction, alkylation and digestion 
steps within and across laboratories.  Therefore, we also calculated the loss and effect 
on CV for addition of stable isotope-labeled peptides pre-desalt vs. post-desalt (see 
below and Supplemental Figure 2 and Supplemental Table 8). Six additional unlabeled 
proteins were added at constant levels to all Phase III plasma samples to serve as 
process controls (Supplemental Table 1). A separate set of depleted plasma samples 
containing 3 different concentrations of the 27 cancer relevant proteins were also 
generated and the spike concentrations of the proteins in these samples were blinded to 
the participants.   
All sample sets were prepared centrally, in triplicate, and shipped to the participating 
sites.  Following the SOP (Supplemental Document 2), each site denatured, reduced, 
alkylated, trypsin digested and desalted each sample and then added 13C/15N-labeled 
peptide standards prior to LC-MRM-MS analysis.  The SSP was again used as 
described, above.  All LC-MRM-MS data were integrated at the individual sites using 
Skyline.  Reports were exported from Skyline in a pre-defined format and further 
processed in QuaSAR 
(http://genepattern.broadinstitute.org/gp/pages/index.jsf?lsid=QuaSAR) to determine 
Limits of Detection and Quantitation, CVs for replicate samples, to construct response 
curves and to evaluate data for interferences.  All data (raw and processed) were 
submitted for review using a central ftp site with controlled access at the National 
Institute of Standards and Technology (NIST).   
Assay Development and Ongoing Monitoring of Site Performance. Purified light 
(12C/14N) and heavy (13C/15N) peptide forms of 125 peptides were used to optimize LC 
gradient and triple quadrupole transition selection (Q1/Q3) for all instrument platforms 
(Supplemental Table 2).  The sequences of 115 of these peptides were derived from 
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the 27 cancer-relevant proteins while 10 peptides were the same as used in our earlier 
study (5). Selection of specific peptides to target from each protein to target was based 
on a combination of empirical data from discovery proteomics experiments (Broad 
Institute, data not shown), Peptide Atlas, The Global Proteome Machine (GPM), and, 
when empirical data were not available, by using the peptide selection algorithm 
ESPPredictor [(35), 
http://www.broadinstitute.org/cancer/software/genepattern/modules/ESPPredictor.html]. 
In Phase I, three to five transitions per peptide were evaluated for interference in 
depleted plasma using AuDIT (50), and the three most abundant transitions with the 
least interference for each peptide were selected to monitor.  Protein digestion was 
optimized to reduce missed cleavage products and achieve maximum peptide recovery 
(see Methods). The final digestion protocol used both Lys-C and trypsin in tandem 
(Supplemental Documents 1 and 2).  The missed cleavage rate for proteins using the 
double digestion protocol was determined to be ca. 20% (36).   
Not all peptides initially selected and analyzed by LC-MRM-MS were used in the final 
analyses.  Peptide performance was assessed by the following criteria.  The peak area 
of the analyte peptide at the concentration above the calculated LOQ (determined in 
Phase II) was defined as the minimum acceptable peak area, and varied by peptide and 
instrument.  Peptides were excluded if the peak areas of the U15N-labeled peptides 
derived from the labeled protein standards (Phase III) were smaller than the minimum 
acceptable peak area. This criterion was applied to maintain consistency in comparing 
Phase II and Phase III data across the same sub-set of peptides, and to ensure that 
reliable quantification could be maintained such that the internal standard area was 
above the LOQ.  This resulted in a total of 96 peptides compared across the two study 
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phases (peptides marked with an asterisk in Table 1). Data from all peptides are 
available in Chorus.   
In order to be included in the cross-instrument comparison, each data set had to be 
generated following the SOP (Supplemental Documents 1 and 2) with only minor 
deviations permitted.  In addition, data sets from each instrument were evaluated using 
the SSP data to ensure instruments were in good working order during each study 
Phase prior to inclusion in data analysis.   Thirteen of fourteen instruments completed 
Phase II while eight instruments completed Phase III. Instruments were excluded from a 
specific phase of the study based on failing the SSP due to large retention time shifts, 
retention time scheduling problems, or unacceptably high peak area CVs.  In addition to 
these objective criteria, three instruments did not continue to Phase III because the sites 
had other commitments and/or lacked funding to continue the studies. Complete 
datasets for all instruments, regardless of inclusion in data analysis, can be found on 
Panoramaweb.org 
(http://proteome.gs.washington.edu/software/panorama/cptac_study9.html). 
Limits of Detection and Quantification.  The LODs and LOQs were determined from 
the response curve data generated at each site for the peptides monitored in Phase II 
and Phase III (Figure 2, Supplemental Tables 4 and 5).  The median peptide LOD 
ranged from 0.053-0.162 fmol/µL for the thirteen instruments in Phase II.  For Phase III, 
the median LODs determined using the synthetic heavy-labeled peptides as internal 
standards ranged from 0.037 to 0.186 fmol/µL for the 8 participating instruments.  This 
corresponds to LODs between 17 ng/mL to 83 ng/mL of protein assuming 100% release 
efficiency of the analyte peptide from the protein (using average protein MW of 50 kDa).  
When U15N-labeled proteins were used as internal standards in Phase III, LODs ranged 
from 0.096 to 0.51 fmol/µL across sites (44 – 230 ng/mL protein concentration in 
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plasma). This increase in LOD is attributed to higher variability exhibited by the U15N-
labeled peptides due to a combination of losses related to proteolytic digestion and 
losses during desalting.	   
The LOD and LOQ achieved in Phase II of this study were compared to our previous 
SID-MRM-MS interlaboratory study in which ten peptides were monitored in neat plasma 
digests [(5), Figure 3, Supplemental Table 6].  Two of the 10 peptides were derived 
from C-reactive protein, a moderately abundant plasma protein, and are readily detected 
in all samples (including the depleted plasma blanks) in both studies. Therefore these 
peptides were not used for this comparison.  The LOD and LOQ of the remaining 8 
peptides were improved between 3 and 5-fold in the current study (Phase II) compared 
to our previous study (5).  The improvement in detection sensitivity is likely due to a 
combination of the increased relative concentration of the monitored analytes in the 
depleted plasma, decreased interference/ion suppression from removal of peptides from 
highly abundant proteins that were depleted and optimization of the chromatographic 
conditions.  
Use of U-15N-labeled Protein Standards for Improved Quantitative Accuracy.  The 
response curves generated in Phase III exhibited less than 100% recovery due to 
incomplete release of analyte peptides from the light proteins and peptide loss from 
desalting post digestion (21, 31). To evaluate the potential to compensate for 
idiosyncrasies in peptide release and recovery post desalt, and to improve quantitative 
accuracy, we added U15N-labeled proteins as internal standards for 27 of the target 
proteins (Figure 1, Phase III).  Labeled proteins were spiked into all samples (i.e., 
response curve concentration points, blank samples containing no added light proteins 
and blinded samples) at 25 fmol/µL prior to digestion. Synthetic 13C/15N peptides were 
introduced post-desalt at 10 fmol/µL to monitor for analyte peptide recovery from both 
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the light and heavy versions of the proteins. When the U15N-heavy peptides derived from 
the U15N-labeled proteins were used to normalize the analyte peptide response (arising 
from the unlabeled protein spikes), the measured concentration more accurately 
reflected the protein amounts spiked into the original samples (Supplemental Figure 1). 
Using heavy protein internal standards, the median peptide recoveries now approached 
100% (97% median value across all sites, all peptides, Supplemental Table 7), 
reflecting improved quantitative accuracy in the calculation of protein concentration in 
the samples. In contrast, median peptide recovery using only labeled peptide standards 
was 34% across the 9 instruments, due to losses occurring during proteolytic digestion 
as well as loss of peptide during the desalting step (see below, Supplemental Figure 2 
and Supplemental Table 8). 
Evaluation of Peptide Loss Related to Digestion and Desalting and Effects on CV 
and Determined LOD.  Apparent loss of peptides during the proteolytic digestion step 
can arise by incomplete digestion of the corresponding proteins or by loss of fully 
released peptides by precipitation, adsorption on surfaces, etc. The loss of peptides 
during proteolysis was assessed using the peak area ratios of 13C/15N-labeled peptides 
spiked pre-desalt to U15N-protein-derived peptide (see Methods).  The median peptide 
loss was ca. 70% (i.e., 30% recovery), with a range in loss from 30% to 99% (i.e., 1% to 
70% recovery) across >96 peptides used in the measurement (Supplemental Figure 2 
and Supplemental Table 8).   
To determine peptide loss due to desalting post digestion, labeled standard peptides 
were added pre- and post-desalt and analyzed by three participating instruments in 
Phase III. Comparing peptide recovery in these sample pairs with the peptide derived 
from the U15N-labeled protein standard enabled estimation of peptide loss due to 
desalting (see Methods for details).  The median loss due to desalting was ca. 27%, with 
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an interquartile range of 13% to 40% (Supplemental Figure 2 and Supplemental Table 
8).  
The effects of SIS peptide addition pre- or post-desalt on CV and LOD were also 
evaluated. Addition of peptides post desalt resulted in higher CVs than for pre-desalt 
addition (Supplemental Figures 2a and 2c, respectively).  The overall precision is better 
above the LOQ when the SIS peptide is added pre-desalt as analyte and SIS peptide 
are affected equivalently during the desalt step.  As expected, the determined median 
peptide LOD was artificially lower (more sensitive) when SIS peptides were added post-
desalt because losses occurring due to desalt are not taken into account. 
Analysis of Blinded Sample Performance.  Sets of samples spiked with peptide (125 
peptides in Phase II) and protein (27 proteins in Phase III) analytes at concentrations 
blinded to the study participants were analyzed at the sites after each response curve 
replicate in Phases II and III.  The blinded sample concentrations were chosen to span a 
range similar to the response curve (0.1 – 75 fmol/µL) and were run in pseudo-random 
order to mimic the analysis of unknown samples in a biomarker verification study.  
Results are shown in Figure 4 and Supplemental Table 9 and allow for direct 
comparison of quantitative accuracy and peptide recovery across the participating 
laboratories and instruments.  In Phase II, the blinded levels of spiked peptides were 
determined using heavy synthetic peptides (Figure 4, panel A), with a median 
concentration of 1.6 fmol/µL and a range of 1.4 - 2.9 fmol/µL across the 13 instruments 
for the 1.8 fmol/µL concentration point (Supplemental Table 9).  The median CVs of 
these measurements were below 20% for 11 out of 13 instruments (Supplemental 
Figure 3), similar to the CVs achieved in the response curve data for samples with 
concentrations ≥ 1.8 fmol/µL  (see below).  Twelve out of thirteen instruments 
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demonstrated CVs well below 15% for the 20 fmol/µL blinded samples and twelve out of 
thirteen had CVs 12% or lower for the 72 fmol/µL point.   
In Phase III, the blinded levels of spiked proteins were determined using both heavy 
synthetic peptides and U15N-labeled protein standards (Figure 4, panels B and C, 
respectively). The lowest concentration point was removed based on lack of robust 
detection at this level in preliminary studies, and the remaining concentrations were 
adjusted to the three values shown (Figure 4B, C). The median concentrations in Phase 
III determined at each of the sites for the spiked proteins using synthetic peptides added 
post-desalt were significantly lower than their actual concentrations, and lower than the 
concentrations determined in Phase II (Figure 4 and Supplemental Table 10. This was 
expected since the peptides being measured were derived from digestion of proteins 
(Phase III) in the sample rather than spiked synthetic peptides (Phase II). When peptides 
derived from the U-15N-labeled proteins were used to calculate concentration, peptide 
recovery (synonymous with accuracy in this context) improves from 30% to 101% for the 
75 fmol/µL sample.  For the three sites that also added the heavy isotope-labeled 
peptides pre-desalt, the median recovery calculated using the SIS peptides was 42%. 
The range of median determined concentrations using protein standards (Figure 4, 
Panel C) was narrower using heavy protein standards and similar to the peptide spikes 
alone (Figure 4, Panel A). The CVs for Phase III are significantly higher for all 
instruments relative to Phase II, reflecting the greater variability introduced by 
incomplete digestion and/or loss of peptides released from the protein spikes as well as 
variable losses from desalting (Supplemental Figure 2).   
Inter- and Intra-laboratory Reproducibility.  The median CV for all peptides at each 
concentration point for each of the participating laboratories and instruments in Phases II 
and III of the study are shown in Figure 5 and Supplemental Table 11.  The CV was 
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calculated for 96 peptides monitored in the assay) from the process replicates analyzed 
(n = 4 for Phase II, n = 4 for Phase III, where 3 replicates were process replicates and 1 
was a technical replicate).  Overall, Phase II (Figure 5A) showed a steep decrease 
(improvement) in intralaboratory CV as the analyte peptide concentrations increased 
above 0.018 fmol/µL, with nine out of thirteen sites having median CVs below 20% at 
0.316 fmol/µL.  In Phase III (Figure 5B), where the majority of the sample processing 
was conducted at the individual sites and protein-level spike-ins were used (with 13C/15N-
labeled peptides as internal standards), the variability was higher at the same protein 
concentrations, most likely due to incomplete digestion and peptide recovery.  The 
median intralaboratory CV values did not fall below the 20% mark until the analyte 
protein concentration exceeded 1.3 fmol/µL.  When the Phase III data were processed 
using the U15N peptides derived from the U15N-labeled proteins vs. the synthetic 13C/15N 
peptides as internal standards, both intra-lab and inter-lab CVs improved above the LOQ, 
indicating the variability observed in the analyte was also observed in the U15N peptide 
standard, further supporting addition of an internal standards as far upstream in the 
workflow as possible (data not shown).     
Interlaboratory CV, which was calculated for each peptide across all sites (n = 52 for 
Phase II and n = 32 for Phase III) were considerably higher.  The median interlaboratory 
CV by peptide was 18% at the 1.3 fmol/ µL concentration point, while in Phase III for the 
same concentration, it was 45% when using 13C/15N peptide spikes post-desalt, and 36% 
when using U15N-labeled proteins.  This calculation of CV takes into account the 
variability between sites, which was found to be much larger in general, particularly 
when more sample handling was involved.  
Monitoring Digestion and Assay Variability with Protein and Peptide Controls.  To 
better assess variability due to protein digestion and sample handling, six unlabeled 
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proteins were spiked into all Phase III samples above the anticipated peptide LOQs (2.5 
fmol/µL) to serve as digestion controls.  The six proteins were well-characterized in our 
previous study (5). In addition eight synthetic 13C/15N-labeled peptides (selected tryptic 
sequences from the six proteins) were added to the samples post-desalt (10 fmol/µL).  
To assess process variability encompassing the digestion and desalt protocol, the CV of 
the raw peak areas of the unlabeled digestion control peptides were determined across 
each sample monitored on each instrument (n = 100-150 sample injections).  Figure 6 
shows the process variability (red bars) for the 8 peptides at one representative site.  
The majority of the peptides (5 out of 8) have raw peak area CVs less than 30% with all 
peptides having CVs of 35% or less.  It is important to note that these CVs are 
calculated with raw peak area, not peak area ratios as are used for quantification and do 
not reflect precision of quantification.  Variability of raw peak areas tends to be higher 
when assessed over an experiment due to variations in the LC and MS, whereas use of 
an internal standard normalizes for this type of variation.  Technical variability, reflecting 
the LC-MRM-MS system performance during the Phase III study, is represented by the 
blue bars in which the raw peak area CVs of the 13C/15N-labeled peptides are plotted.  All 
eight peptides had CVs less than 25%, indicating good system performance over the 
course of the study.   
 
 
 
Discussion  
The current study builds upon the prior work of Addona et al. (5), and focuses on 
defining and addressing the issues encountered in the development and execution of 
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large-scale SID-MRM-MS assays. Here we designed the largest inter-laboratory 
investigation to date, targeting 125 peptides derived from 27 cancer-relevant proteins 
and 6 control proteins to precisely and reproducibly measure the analytes in human 
plasma at 11 laboratories using 8 distinct instrument platforms and a total of 14 LC-MS 
instrument configurations. We evaluated additional aspects of SID-MRM-MS assay 
development and application, including the use of U15N-labeled protein standards for 
improved quantitative accuracy, use of internal digestion controls to monitor intra- and 
inter-lab reproducibility, the benefits of immuno-depletion of abundant plasma proteins to 
increase sensitivity for quantification of protein analytes, use of pre-packed columns and 
column heaters to improve assay reproducibility, uniform data processing using vendor 
neutral Skyline and QuaSAR software, and use of a SSP for monitoring instrument 
performance throughout assay development and study phases.   
Successful Assay Development Requires Optimization of Multiple Experimental 
Parameters. Substantial work was performed to develop the highly multiplexed assay 
described herein.  Digestion studies were performed to select the best digestion 
conditions for the target proteins in plasma, minimizing missed cleavage products and 
maximizing peptide recovery.  The precursor/product ion pairs used for each of the 8 
different LC-triple quadrupole configurations were selected and prioritized by ion 
intensity and lack of interferences.  Importantly, the selected transitions were tested in 
the presence of digested, depleted plasma to account for interferences from the sample 
matrix or from the standards themselves.  Collision energy values were based on 
previously determined linear regression equations for each vendor platform in Skyline, 
based on charge and m/z of the analyte peptides (40).  Of note, different vendor 
platforms had different lists of transitions for each target peptide, based on their 
empirical performance.  A highly detailed SOP was written and circulated with the 
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sample kits to ensure uniform sample handling, chromatography and data acquisition 
across sites.  
Peptide selection was based on both empirical data and predictive algorithms.  Between 
1 and 5 peptides were selected for each protein, adhering to the usual selection rules 
(see Methods and 2, 35).  However, not all peptides had the same level of performance 
by LC-MRM-MS, as was revealed during Phase I (method development). We found that 
we could not rely solely on historic targeted data or predictive algorithms which 
necessitated obtaining empirical data on the peptides in the targeted assay. One peptide 
containing an N-terminal carboxyamidomethyl cysteine (CGTGIVGVFVK, PDLI1) was 
found to spontaneously cyclize at the N-terminus with associated loss of hydrogen 
[observed in synthetic standard, data not shown, (51). Other peptides had poor 
chromatographic peak shapes or were found to elute over several minutes rather than 
the 7-15 second FWHM elution time observed for the majority of the peptides.  
Additionally, and important in Phase III, not all peptides were efficiently recovered from 
the protein during digestion and/or post-desalting, resulting in a wide range of recoveries 
of the U-15N peptides generated from the U-15N-protein standards, ranging from “not 
detected” to ca. 70% recovered. These effects were observed despite having selected 
proteotypic peptides for MRM assay development based largely on prior observation 
from discovery proteomics data in the literature. However, neither prior observation of 
peptides or prediction tools for selecting the best responding peptides from proteins are 
predictors of completeness of digestion or recovery of peptides post digestion. In the 
present study, the largest source of loss of target peptides occurred during the digestion 
step, with a median loss of ca. 70% across the nearly 100 peptides.  Losses due to the 
digestion step were over 2-times greater than losses due to desalting for the set of 
peptides studies here.  Unfortunately, no predictive tools are available to score peptide 
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release/recovery efficiency during protein digestion, which is the dominant reason for the 
lower success rate in Phase III.   
Assessment of the data and comparing multiple peptides per protein allowed the option 
to select the best performing peptides for subsequent calculations and site-to-site 
comparisons for assay metrics.  Only those peptides found to have detectable signal in 
the U-15N-labeled form in Phase III were used for calculations. In Phase III, the peptide-
level success rate for detection was 83%, while the success rate for detection and 
quantification of proteins was 93%, with peptides for 25 out of 27 protein spikes detected 
and quantified.  This likely reflects average success rates for detection in targeted 
peptide quantification when peptide prediction tools are used and empirical data are not 
always available.   
System Suitability Standards and Rigorous SOPs Can Greatly Reduce Problems in 
Assay Construction.  Highly multiplexed MRM-MS assays require an elevated level of 
system performance in order to target >100 peptides in a single LC run.  Through 
development and utilization of SOPs and a SSP we have demonstrated here that highly 
multiplexed (100’s of analytes), quantitative assays having high sensitivity, well defined 
specificity and good reproducibility within and across labs can be developed and 
implemented. Each site was required to acquire SSP data before and throughout the 
study to track system performance. Instruments that did not maintain good retention time 
stability, such that peaks were cut off during acquisition or missed entirely and could not 
provide data for the 4 process replicates were removed from subsequent data analysis.  
In addition, instruments with elevated peak area CVs for the SSP, either before (>25%) 
or throughout the study (>45%), were also eliminated because peak area CV of a SSP 
has been shown to correlate with assay sensitivity (33). The use of a SSP was evaluated 
as a proof-of-concept for data evaluation in this study and was new to some of the 
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participating laboratories. As a result, some of the sites failed to examine their SSP data 
in real-time leading to deterioration in performance that was not identified and corrected 
during the study, but instead was identified post-acquisition.  In this study, the most 
common reasons for repeated sample injections were related to shifting retention times 
in the chromatography, or decreased MS signal due to a dirty ion source. Sites that 
followed the SOP and used the SSP produced superior results. 
Use of Peptide and Protein Controls Allows for Monitoring of Technical and 
Process Variation.  Phase III of our study incorporated two additional controls to 
monitor both technical and process variability.  Technical variation throughout the assay 
was monitored by determining the raw peak area CV for 8 synthetic 13C/15N-labeled 
peptides that were spiked into each sample at 10 fmol/µL.  This approach allowed for 
monitoring variability introduced through the LC or MS and could be considered 
analogous to the SSP.  Use of Skyline to visualize the data allowed for a quick 
assessment of variability at the individual sample level based on raw peak area as well 
as across the entire study (peak area CV, Figure 6).  Technical variability in LC-MS 
instrument performance between the peptide controls and the SSP were compared for 
Phase III for the 9 different instruments and showed good agreement in general.  
Sample to sample deviations could be caused by either LC-MS issues or fluctuations in 
the sample background, which could affect the overall signal intensities of the technical 
control peptides.  Any discord between the technical peptide controls and the SSP is 
likely sample related.  Process variability was tracked through the use of 6 unlabeled 
protein standards spiked into each sample at low concentrations.  Monitoring the peak 
area ratio between the light, protein-derived peptides and the heavy synthetic peptides, 
as well as the raw peak area of the protein-derived peptides, provided an assessment of 
the variability introduced due to digestion and desalting for each data set.  In this study, 
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the same information could be obtained by monitoring the peptides derived from the 
U15N -labeled proteins, which were compared to the unlabeled process control proteins. 
Limits of Quantification are Substantially Improved by Immunoaffinity Depletion 
and to a Lesser Extent by Use of Newer LC-MS Technology Significant 
improvements in sensitivity were achieved in the present study as compared to our 
previous work. The principal, but not sole difference, was the use of immunoaffinity 
depletion of plasma for these studies.  Depletion of the top 14 most abundant human 
plasma proteins decreased sample complexity and allowed a higher effective 
concentration of monitored analytes to be loaded on the column.  LOQs were improved 
3-5 fold (at the peptide level) relative to our earlier study while simultaneously increasing 
assay multiplex level more than 10-fold. The increase in sensitivity afforded by depletion 
is best captured at the protein level, which was over 20-fold for the 7 proteins compared 
between the studies. This value agrees well with previously published data in which the 
effects of immuno-depletion were evaluated (19). Optimization of the reversed phase 
gradient to improve peptide separation likely also contributed to the improvement 
observed in the LOQ.  
The use of newer technologies such as latest generation triple quadrupole mass 
spectrometers with faster dwell times and brighter ion sources, as well as UHPLC 
systems for improved chromatographic resolution did enhance sensitivity, but less than 
we initially anticipated (Figure 2). The differences in determined LODs between different 
generations of instruments from different vendors that were operating properly and that 
met SSP performance criteria generally varied by less than 2-fold (Figure 2; instruments 
not meeting performance standards were excluded from these results).  The largest 
differences (for example, between sites 56C, 65A and the rest of the sites/instruments) 
were likely due to small differences in chromatographic configurations. For example, the 
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AB SCIEX 4000 QTRAPs used PicoFrits while the AB SCIEX 5500 QTRAPs used chip 
columns in parallel with post-column attachment to ion source which introduced some 
band broadening. Another example is the Waters Xevo TQ that employed a trap column 
while the Waters TQS system did not. We conclude that while use of the newest 
technology has the potential to improve sensitivity, signal to background biological noise 
remained the principal limiter on assay sensitivity.  The two methods that have been 
clearly demonstrated to decrease biological noise while retaining high analyte signal are 
fraction MRM (fMRM) and SISCAPA also referred to as immunoMRM (9, 19, 28-31) 
Reproducibility of Assays Within and Across Sites.  The variability observed at each 
site (intralaboratory CV) was found to range from 13 to 39% (median of 15% across 
sites) at the 0.316 fmol/ µL concentration point for the 13 sites in Phase II.  The 
interlaboratory CV, calculated according to Hoofnagle (52) was 31% at the 1.3 fmol/ µL 
concentration point when using U15N-labeled protein standards.  The variability observed 
in Phase II is a measurement of technical variability in the LC-MS platforms used at each 
site, and was found to be improved over that found in our previous study.  This 
improvement can be attributed to several factors implemented in this study, including a 
more rigorous SOP, the use of pre-packed columns and column heaters, and close 
monitoring of instrument performance using a SSP, which when combined will minimize 
technical variability.  Phase III variability was higher (58% at 0.316 fmol/ µL and 46% at 
1.3 fmol/ µL) than in Phase II, which was not surprising considering that reduction, 
alkylation, digestion and other sample handling steps were performed at each instrument 
site rather than centrally. Use of the U15N-labeled proteins improved variability for many 
peptides as compared to the 13C/15N-labeled peptides (42% at 0.316 fmol/ µL and 31% 
at 1.3 fmol/ µL), further supporting their use for both precise and accurate quantification 
by LC-MRM-MS.  
 36 
Samples were immunoaffinity depleted of abundant plasma proteins at a single site prior 
to further analysis (see Methods). Therefore, variability that could be introduced by the 
abundant protein depletion step was not directly measured.  Assessing the contribution 
of this step to the variability would have required additional experiments involving 
depletion of all process replicates in Phase III samples at each protein concentration at 
each of the sites.  While time and funding were limiting factors preventing us from 
evaluating this step in the current study, several published studies have evaluated the 
reproducibility of column-based abundant protein depletion and have found it to be 
robust and reproducible.  The Smith laboratory at PNNL evaluated protein recovery and 
depletion efficiency using the IgY-12 column from Sigma, alone (53) or in combination 
with a second column that removes an additional ca. 50-60 proteins (so-called 
“Supermix” strategy (54).  In both cases the reproducibility of process replicates was 
<20% based upon the number of proteins identified and spectral counting (n=5). The 
Carr laboratory (55) used IgY-12 column depletion and peptide fractionation prior to SID-
MRM-MS to quantify low-level candidate cardiovascular biomarkers in plasma from 
multiple patients and multiple timepoints/patient. They found the total process variability 
(%CV), including that introduced by SCX-based peptide fractionation prior to MRM, to 
range from <1%  to a maximum of 35% across three process replicates of 24 samples.  
This degree of variability is similar to, and no higher than, the intra- and interlaboratory 
CVs presented here as well as that reported in our previous interlaboratory study (5).  
Together these prior studies suggest that minimal additional variation is introduced 
within laboratories by use of column-based abundant protein depletion methods.  
Factors that could affect inter-laboratory reproducibility include incomplete wash and 
regeneration steps and lot-to-lot variability of the depletion columns. One impact of 
incomplete depletion could be a change in the LOD/LOQ for some analytes caused by 
ion suppression from peptides derived from abundant proteins that were not adequately 
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depleted.  However, unless detection of the analyte was near the noise level in the MS, 
such variation in depletion would not likely result in either a failure to be able to detect 
the analyte or in the ability to quantify that analyte relative to the heavy internal standard 
peptide as both analyte and labeled standard would be affected equally by any ion 
suppression.  Protein analytes partially bound to proteins targeted by the depletion 
column could also have their levels change in the depleted plasma sample.  In such a 
case, the values measured for peptides from that protein could be lower than for a 
properly operating column. 
Use of Labeled Internal Standard Proteins Improves Quantitative Accuracy.  This is 
the largest study to date utilizing U15N-labeled proteins as internal standards for protein 
quantification. The U15N-labeled proteins were expressed and purified using the same 
process as the unlabeled proteins used in this study and, in all regards, should behave 
quite similarly. An added benefit to using heavy-labeled proteins as internal standards is 
the ability to monitor multiple peptides from each protein.  In cases where digestion is 
incomplete, resulting in missed cleaved peptides or in cases where additional peptides 
from the protein would strengthen the statistics of the measurement, as long as the 
heavy-labeled protein behaves the same way as the endogenous protein, the additional 
peptide forms can be readily monitored.  Such experiments are especially tractable 
using instruments with high resolution, accurate mass capabilities where the accurate 
mass measurement of the precursor and the fragments significantly improves the 
confidence of the analyses and selection and optimization of transitions is not 
necessarily required (15, 56).   
Blinded samples were incorporated in our study to model real-world sample analysis 
such as would be encountered in a biomarker verification study and to evaluate 
consistency of results across laboratories. The accuracy obtained in Phase III of the 
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study, where laboratories did all sample processing themselves, was 101% when using 
the U15N-labeled proteins for normalization.  While use of heavy-labeled proteins in the 
present study greatly improved quantitative accuracy for measurement of the light 
versions of the same proteins also expressed in E. coli, their use in general for 
quantification of endogenous proteins may not be as accurate.   Discrepancies could 
arise as a result of modifications (e.g., cleavage forms, posttranslational modifications, 
etc.) present in the endogenous protein that are not present in the heavy-labeled protein 
standard.  In studies where accuracy is a requirement, demonstrations of parallelism of 
the internal standard to the endogenous protein in the sample matrix should be carried 
out (10). 
When heavy-labeled proteins are not available, using synthetic 13C/15N-labeled peptides 
is the next best option, and is likely a necessity for quantification of most 
posttranslational modifications, which are difficult or impossible to recapitulate accurately 
in a recombinant protein.  However, SIS peptides added post-digestion and pre-desalt 
cannot account for variability in peptide recovery from the digestion step.  Peptide 
recovery from the digestion step ranged from 1% to 70% for the 96 peptides in the 
present study. While it makes sense to avoid peptides that are predicted to have a 
higher mis-cleavage propensity (i.e., double basics at either end of the peptide or acidic 
residues in close proximity to the cleavage sites), such mis-cleaved peptides are not 
necessarily recovered to a lesser extent from the digest than peptides that are predicted 
to be fully tryptic (57).  A mis-cleaved form may be the dominant form of the peptide 
released from the protein and/or it may have solubility properties that are superior to that 
of the fully tryptic.  Adding SIS peptides or “wing peptides” to the sample pre-digest (47, 
58) may improve accuracy when using heavy labeled peptides as substitutes for labeled 
proteins. 
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While uniformly 15N-labeled proteins are commonly synthesized for NMR (59), they are 
not the ideal choice for heavy-labeled protein reference standards for mass spectrometry. 
The mass shift relative to the unlabeled peptide varied depending on the number of 
nitrogen atoms per peptide.  Shorter peptides with lysine at the C-terminus tend to have 
precursor masses that are close (<2 amu) to the 13C/15N-labeled synthetic peptides. This 
makes the internal standard peptide difficult to distinguish from the analyte peptide on 
instruments like triple quadrupole MS systems that use relatively wide (0.4 to >1.0 mass 
unit) precursor selection windows. In addition, the monoisotopic (M+H)+ peptide masses 
were typically not the dominant precursor ions derived from the intact proteins that had 
isotopic purities of >98% (Supplemental Figure 4 and Supplemental Table 12). In 
future studies, the proteins would ideally be produced with only specific amino acid 
residues labeled (e.g., 13C/15N-labeled lysine and arginine) at very high isotopic purity to 
minimize under-labeled forms of each peptide as well as allow for fixed mass shifts for 
each peptide.  
In conclusion, this study explored the feasibility of developing and implementing a highly 
multiplexed SID-MRM-MS assay targeting 125 peptides in depleted plasma on 14 
different triple quadrupole instrument platforms.  Improved LOQs were achieved through 
the use of depleted plasma, LC gradient optimization, and reduced sample load per 
injection.  Reproducibility was improved over our previous study due to addition of a SSP, 
the use of pre-packed columns and column heaters as well as protein internal standards.  
Improved quantitative accuracy was achieved through the use of U15N-labeled proteins 
and addition of the synthetic 13C/15N-labeled peptide standards earlier in the sample 
handling workflow.  The use of Skyline made it possible to develop targeted assays on 
all instrument platforms and integrated data for further processing and analyses in 
QuaSAR.  We demonstrated the ability to use proteins and synthetic peptides as 
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process and technical controls that can be used in any type of targeted experiment to 
assess and track variability from sample to sample throughout a study.  The evaluation 
and rigorous testing, in addition to development of tools and technologies to improve the 
precision and accuracy of SID-MRM-MS resulted in a plethora of data for benchmarking 
targeted MRM-MS workflows as well as developing additional computational tools for 
analysis.   
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Figure Legends 
Figure 1. Schematic of the experimental design of the three phases of the study. Phase I 
consisted of method development and optimization of the sample handling, LC, and MS 
parameters for peptide detection. Phase II was generation of the peptide-level response 
curve in which 125 light peptides were spiked into depleted, digested plasma at 9 
concentrations and 125 13C/15N peptides were spiked in as internal standards and 750 
transitions were monitored on the different LC-MRM-MS platforms.  Phase III introduced 
unlabeled (light) and uniformly 15N-labeled proteins into the workflow, which were spiked 
into depleted plasma to generate a 9-point response curve.  Samples were further 
processed at the individual sites to denature, reduce, alkylate, desalt and reconstitute 
the samples with 13C/15N peptide standards for LC-MRM-MS analysis, resulting in a total 
of 1095 transitions for each method.  Skyline was integral from Phase I through Phase III 
for transition selection, method building, retention time scheduling, and data integration 
across the different vendor platforms.    
 
Figure 2.  Limit of Detection distributions for the peptides monitored at each site.  The 
black bar in each box represents the median peptide LOD at that site, the box 
represents the interquartile range and the whiskers represents 3x the interquartile range.  
 50 
Outlier peptides are shown as black dots.  Panel A represents data from Phase II for the 
13 instruments completing the study.  Panel B shows the LOD distribution for the 8 
instruments that completed Phase III, with the synthetic 13C/15N peptides used as internal 
standards.  Panel C represents the same Phase III data, except the U15N-peptides, 
derived from the U15N-proteins, were used as internal standards.   
 
Figure 3.  Comparison of the Limits of Detection (LODs) for the eight peptides from the 
Addona et al., 2009 Study and the current study (Phase II).  The box and whisker chart 
represents the distribution of LODs from the participating sites in both studies for the 
peptide-level spike experiment.   
 
Figure 4.  Evaluation of the accuracy of determined concentrations for 125 peptides in 
the blinded samples:  Sets of samples were spiked with peptide (125 peptides in Phase 
II) and protein (27 proteins in Phase III) analytes at concentrations blinded to the study 
participants were analyzed at the sites after each response curve replicate in Phases II 
and III. Panel A shows the four blinded sample concentrations and the range of peptide 
concentrations detected at each site in Phase II.  Panels B and C represent the Phase III 
blinded sample concentrations determined when using the 13C/15N peptides (panel B) or 
the U15N-proteins (panel C) as internal standards.  The light blue lines represent the 
actual concentrations of spiked proteins.  Note that in Panel B all measured 
concentrations are well below the actual concentrations when calculating concentration 
based on spiked heavy peptides.  Concentration values are much closer to the actual 
values in Panel C where concentration values were relative to peptides derived from the 
digestion of U15N-labeled internal standard proteins.  
 51 
 
Figure 5.  Reproducibility plots for Phases II and III at each sample concentration. The 
median peak area %CV for 115 peptides is shown for Phase II (panel A) and Phase III 
(panel B) for all sites.   
Figure 6.  Technical and Process Variability Assessed from Digestion Controls and SIS 
Peptide Spikes for Phase III.  Six unlabeled (light) proteins were spiked into all samples 
pre-digestion at a fixed concentration (2.5 fmol/µL). The red bars represent the CV of the 
raw peak areas arising from the light peptides, and reflect the process variability (due to 
digestion, desalt, and sample handling) of the assay for 40 individual samples.  Eight 
13C/15N peptides were spiked into all samples post-desalt at 10 fmol/µL.  The blue bars 
represent the CV of the raw peak areas from the 13C/15N peptides, and reflect the 
technical variability of the LC-MRM-MS measurements.  Here, we see the process 
variability exceeds the technical variability for all peptides and is 35% or less, based on 
raw peak area.  The technical variability is 25% or less for all peptides over the 
measurement of 40 different samples, and is 20% or less for 6 of the 8 peptides.  This is 
an example from Phase III, site 56B90, plotted in Skyline.   
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